Cisplatin-based chemotherapy and hyperfractionated radiotherapy for stage III non-small cell lung cancer: survival and patterns of failure after long follow-up-Reference-Cited by-同舟云学术

Cisplatin-based chemotherapy and hyperfractionated radiotherapy for stage III non-small cell lung cancer: survival and patterns of failure after long follow-up

Published:2002-06 Issue:5 Volume:4 Page:250-254
ISSN:1575-3018
Container-title:Revista de Oncología
language:en
Short-container-title:Rev Oncol

Author:

Gutiérrez Martín Tejedor,Álvarez Juan José Valerdi,Fraile Begoña Bermejo,Urdaniz Juan Ignacio Arraras,García Ruth Vera,Rosillo Francisco Molina,Tomé Juan José Albistur

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/BF02732509.pdf

Reference20 articles.

1. LeChevalier T, Arrigada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991;83:417–23.

2. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 1992;326:524–30.

3. Tejedor M, Valerdi J, Lopez R, et al. Mitomycin, cisplatin, and vindesine followed by radiotherapy combined with cisplatin in stage III non-small cell lung cancer: long-term results. Int J Radiat Oncol Biol Phys 1995;31:813–8.

4. Cox JD, Azarnia N, Byhardt RW, et al. A randomised phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with total greater than or equal to 69.6 Gy in favourable patients with Radiation Therapy Oncology Group stage III non-small cell lung carcinoma; report of Radiation Therapy Oncology Group 83.11. J Clin Oncol 1990;8:1543–55.

5. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–81.